OXFORD, England--(BUSINESS WIRE)--Zyoxel, the world’s leading expert for advanced in vitro 3D liver models for drug discovery and drug testing, has announced preliminary results from a testing by Sanofi on Zyoxel’s LiverChip™ platform for drug metabolism and pharmacokinetic (DMPK) studies. Sanofi employed a variety of morphological, genetic and functional analyses to fully characterise the LiverChip™ system, the full findings of which will be presented as part of Zyoxel’s In Vitro Liver Technology Symposium taking place on December 10, 2013 in Oxford, UK.
Help employers find you! Check out all the jobs and post your resume.
